April 30, 2018 / 12:38 PM / 5 months ago

BRIEF-Keryx Biopharmaceuticals Sees Total Revenue For Qtr Ended March 31, 2018 Between $21.0 Mln And $22.5 Mln

April 30 (Reuters) - Keryx Biopharmaceuticals Inc:

* KERYX BIOPHARMACEUTICALS SEES TOTAL REVENUE FOR QUARTER ENDED MARCH 31, 2018 OF BETWEEN $21.0 MILLION AND $22.5 MILLION - SEC FILING

* SAYS CEO AND PRESIDENT GREGORY MADISON RESIGNED

* APPOINTED JODIE MORRISON AS INTERIM CHIEF EXECUTIVE OFFICER

* REDUCED SIZE OF BOARD FROM EIGHT DIRECTORS TO SEVEN DIRECTORS Source text: [bit.ly/2w0gKQT] Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below